Glutathione in Ischemia-Induced Hippocampal Injury: Comparison
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by Youichirou Higashi.

Stroke is a major cause of death worldwide, leading to serious disability. Post-ischemic injury, especially in the cerebral ischemia-prone hippocampus, is a serious problem, as it contributes to vascular dementia. Many studies have shown that in the hippocampus, ischemia/reperfusion induces neuronal death through oxidative stress and neuronal zinc (Zn2+) dyshomeostasis. Glutathione (GSH) plays an important role in protecting neurons against oxidative stress as a major intracellular antioxidant. In addition, the thiol group of GSH can function as a principal Zn2+ chelator for the maintenance of Zn2+ homeostasis in neurons. These lines of evidence suggest that neuronal GSH levels could be a key factor in post-stroke neuronal survival. In neurons, excitatory amino acid carrier 1 (EAAC1) is involved in the influx of cysteine, and intracellular cysteine is the rate-limiting substrate for the synthesis of GSH. Recently, several studies have indicated that cysteine uptake through EAAC1 suppresses ischemia-induced neuronal death via the promotion of hippocampal GSH synthesis in ischemic animal models.

  • glutathione
  • ischemia
  • hippocampus
  • zinc
  • oxidative stress
  • excitatory amino acid carrier 1

1. Introduction

Stroke is one of the most frequent causes of death worldwide and a major cause of serious disability. Lifestyle factors that have been shown to increase the risk of stroke include smoking; lack of physical activity; being overweight; and increased intake of salt, alcohol, and fat. These factors also impact on outcomes in patients with stroke. According to a systematic analysis from 2016, there were 80.1 million prevalent cases of stroke, 5.5 million deaths, and 116.4 million disability-adjusted life years resulting from stroke globally that year [1]. In recent years, although the rate of deaths due to acute ischemic stroke has declined because of the introduction of new therapeutic strategies and specialized care, ischemic stroke survivors continue to suffer from disabilities [2]. In particular, ischemia-induced damage to the hippocampus, the main brain structure related to learning and memory [3], is recognized as a serious problem, as it leads to cognitive impairment [4].
The pathophysiological mechanisms underlying ischemia-induced hippocampal damage have been studied intensively. Oxidative stress, a hallmark of brain ischemia, has been identified as a major factor. It results from the increased generation of reactive oxygen species (ROS) and reactive nitrogen species, which lead to apoptosis and necrosis of neurons [5,6][5][6]. Another factor is the disruption of zinc (Zn2+) homeostasis in the hippocampus. Zn2+ levels are maintained at a constant level in the adult mammalian brain, including the hippocampus, in which Zn2+ participates in normal physiological brain functions, such as learning and memory [7]. However, ischemia/reperfusion disrupts neuronal Zn2+ homeostasis, resulting in neuronal cell death within the hippocampus [8]. Therefore, not only oxidative stress but also the disruption of neuronal Zn2+ homeostasis are recognized as important therapeutic targets for the treatment of ischemia-induced hippocampal injury.
Glutathione (GSH) is the most abundant low molecular weight thiol compound within cells, and it plays a crucial role in cell defense not only against oxidative stress but also against the disruption of Zn2+ homeostasis. In neurons, GSH levels are predominantly regulated by excitatory amino acid carrier 1 (EAAC1), which can transport cysteine, a substrate for GSH synthesis. Accumulating evidence indicates that EAAC1 gene deletion exacerbates ischemia-induced hippocampal damage via impaired Zn2+ homeostasis as well as oxidative stress [9], and that diurnal fluctuations in EAAC1 levels affect susceptibility to ischemia-induced neuronal cell death in the hippocampus [10]. These findings suggest that neuronal GSH levels regulated by EAAC1 are crucial in this context.

2. Protective Roles of Glutathione (GSH) in Ischemia-Induced Hippocampal Injury

2.1. Anti-Oxidative Role of GSH in Ischemia-Induced Oxidative Stress

Cerebral ischemia leads to a marked increase in oxidative stress resulting from the generation of ROS, such as superoxide, hydrogen peroxide, and hydroxyl radicals [5]. Oxidative stress can rapidly damage many components of the cell, including lipids, proteins, and DNA, whereby it contributes to the progression of neuronal cell death after ischemic stroke [11,12,13][11][12][13]. Therefore, oxidative stress is recognized as one of the major mediators of cerebral ischemia/reperfusion-induced hippocampal injury [6,14,15][6][14][15].
GSH is a major endogenous component of the cellular antioxidant defense. It is capable of scavenging various ROS directly. Research has demonstrated that the order of GSH reactivity towards the radicals is OH > OCH3 > OOH > OOCCl3 > OOCHCH2 > OOCH3, and that the rate constants range from 2.02 × 104 M−1 s−1 to the diffusion limit (7.68 × 109 M−1 s−1) [16]. These findings indicate that GSH is an excellent free radical scavenger. On the other hand, GSH is also known to act as a substrate for a number of glutathione peroxidases to detoxify ROS [17]. During these reactions, GSH is oxidized and converted into glutathione disulfide (GSSG), which is subsequently reduced to GSH by glutathione reductase [18]. However, cellular GSH levels can be lowered by the export of GSSG when the production of the latter exceeds the capacity for recycling to the former, indicating that this antioxidative defense system cannot offset oxidative stress [19,20][19][20]. Indeed, many studies have demonstrated that the brain content of endogenous GSH is depleted during ischemia/reperfusion [21[21][22][23],22,23], and that treatment with GSH or glutathione monoethyl ester, a cell-permeable derivative of GSH, ameliorates ischemia-induced oxidative damage, including DNA and lipid oxidation in the hippocampus [24,25][24][25]. These observations suggest that maintaining neuronal GSH levels is an important constituent in protecting neurons against oxidative stress in the post-ischemic hippocampus (Figure 1).
Figure 1. Mechanisms of GSH protection against hippocampal neuron damage following brain ischemia. The abbreviations are as follows: cysteine (Cys), glutamate (Glu), glycine (Gly), excitatory amino acid carrier 1 (EAAC1), glutathione (GSH), glutathione disulfide (GSSG), GSH reductase (GR), GSH peroxidase (GPx), reactive oxygen species (ROS).
Interestingly, Won et al. demonstrated that the GSH levels in CA1 pyramidal neurons were decreased during the first few hours of ischemia/reperfusion, accompanied by increased superoxide levels; conversely, the prevention of ischemia/reperfusion-induced increase in superoxide production using an inhibitor of nicotinamide adenine dinucleotide 3-phosphate oxidase, a major source of ROS, was found to suppress the decline in GSH in post-ischemic neurons [26]. On the other hand, they also showed that mice in which neuronal GSH levels were maintained by treatment with N-acetyl cysteine (NAC), a cell-permeable precursor of GSH, exhibited a reduction in neuronal oxidative stress and neuronal cell death in the hippocampus following ischemia/reperfusion [26]. These findings indicate that the depletion of neuronal GSH is both a result and a cause of neuronal oxidative stress following ischemia/reperfusion. In contrast, changes in the levels of GSH in post-ischemic glial cells, such as astrocytes and microglia, remain to be elucidated. Astrocytes play an important role in the synthesis of neuronal GSH by supplying precursor molecules [27]. Therefore, it is necessary to clarify the role of glial GSH in neuronal survival in the post-ischemic hippocampus.

2.2. GSH Protects Neurons from Ischemia-Induced Disruption of Intracellular Zn2+ Homeostasis

Zn2+ is involved in hippocampal injury following brain ischemia. In the mammalian brain, most of the Zn2+ is bound to specialized Zn2+ proteins—for example, metallothionein and transcription factors [28]. A smaller part of it is concentrated in the presynaptic vesicles in a subset of glutamatergic neurons throughout the forebrain, especially in the hippocampus [29,30,31][29][30][31]. Therefore, the intracellular free Zn2+ concentration in the hippocampus is considered to be very low under normal physiological conditions [28]. However, the stored Zn2+, along with the protein-bound portion, is massively released during ischemia and the onset of reperfusion, subsequently accumulating within hippocampal neurons [32,33,34,35,36,37,38][32][33][34][35][36][37][38]. The prevention of this process using Zn2+ chelators, including calcium disodium ethylenediamine tetraacetate and clioquinol, has been shown to protect hippocampal neurons from ischemia-induced neurodegeneration [8[8][39],39], suggesting that the ischemia-induced disruption of neuronal Zn2+ homeostasis contributes to neurodegeneration in the hippocampus.
The thiol moiety of GSH has a high affinity for Zn2+ through non-enzymatic conjugation. Treatment with GSH protects neurons against Zn2+ accumulation-induced cell toxicity [40]. The replenishment of GSH using NAC reduces Zn2+ accumulation and neurodegeneration in the post-ischemic hippocampus [41]. These findings suggest that GSH acts as an intrinsic factor that buffers intracellular Zn2+ concentrations to prevent the ischemia-induced disruption of Zn2+ homeostasis; in addition to its antioxidative activity, this mechanism protects neurons (Figure 1).
In contrast, Zn2+ binds and inhibits glutathione reductase and peroxidase, the major enzymes of the glutathione redox cycle [42,43][42][43]. Chen and Liao demonstrated evidence indicating that Zn2+ entry into neurons causes a decrease in intracellular GSH levels and eventually triggers neuronal cell death [40]. GSH can suppress the ischemia-induced disruption of Zn2+ homeostasis, but this function may be affected by the accumulation of Zn2+ in neurons.


  1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 459–480.
  2. Feigin, V.L.; Krishnamurthi, R. Public health strategies could reduce the global stroke epidemic. Lancet Neurol. 2010, 9, 847–848.
  3. Izquierdo, I.; Medina, J.H. Memory formation: The sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol. Learn. Mem. 1997, 68, 285–316.
  4. Schaapsmeerders, P.; van Uden, I.W.M.; Tuladhar, A.M.; Maaijwee, N.A.M.; van Dijk, E.J.; Rutten-Jacobs, L.C.A.; Arntz, R.M.; Schoonderwaldt, H.C.; Dorresteijn, L.D.A.; de Leeuw, F.E.; et al. Ipsilateral hippocampal atrophy is associated with long-term memory dysfunction after ischemic stroke in young adults. Hum. Brain Mapp. 2015, 36, 2432–2442.
  5. Oliver, C.N.; Starke-Reed, P.E.; Stadtman, E.R.; Liu, G.J.; Carney, J.M.; Floyd, R.A. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc. Natl. Acad. Sci. USA 1990, 87, 5144–5147.
  6. Rodrigo, R.; Fernández-Gajardo, R.; Gutiérrez, R.; Matamala, J.M.; Carrasco, R.; Miranda-Merchak, A.; Feuerhake, W. Oxidative stress and pathophysiology of ischemic stroke: Novel therapeutic opportunities. CNS Neurol. Disord. Drug Targets 2013, 12, 698–714.
  7. Takeda, A. Zinc homeostasis and functions of zinc in the brain. Biometals 2001, 14, 343–351.
  8. Koh, J.Y.; Suh, S.W.; Gwag, B.J.; He, Y.Y.; Hsu, C.Y.; Choi, D.W. The role of zinc in selective neuronal death after transient global cerebral ischemia. Science 1996, 272, 1013–1016.
  9. Won, S.J.; Yoo, B.H.; Brennan, A.M.; Shin, B.S.; Kauppinen, T.M.; Berman, A.E.; Swanson, R.A.; Suh, S.W. EAAC1 gene deletion alters zinc homeostasis and exacerbates neuronal injury after transient cerebral ischemia. J. Neurosci. 2010, 30, 15409–15418.
  10. Aratake, T.; Higashi, Y.; Hamada, T.; Ueba, Y.; Shimizu, T.; Shimizu, S.; Yawata, T.; Ueba, T.; Saito, M. The role of diurnal fluctuations in excitatory amino acid carrier 1 levels in post-ischemic hippocampal Zn2+ accumulation. Exp. Neurol. 2021, 336, 113538.
  11. Kapoor, M.; Sharma, S.; Sandhir, R.; Nehru, B. Temporal changes in physiological and molecular markers in various brain regions following transient global ischemia in rats. Mol. Biol. Rep. 2019, 46, 6215–6230.
  12. Kho, A.R.; Choi, B.Y.; Lee, S.H.; Hong, D.K.; Lee, S.H.; Jeong, J.H.; Park, K.H.; Song, H.K.; Choi, H.C.; Suh, S.W. Effects of protocatechuic acid (PCA) on global cerebral ischemia-induced hippocampal neuronal death. Int. J. Mol. Sci. 2018, 19, 1420.
  13. Love, S. Oxidative stress in brain ischemia. Brain Pathol. 1999, 9, 119–131.
  14. Nikonenko, A.G.; Radenovic, L.; Andjus, P.R.; Skibo, G.G. Structural features of ischemic damage in the hippocampus. Anat. Rec. 2009, 292, 1914–1921.
  15. Wang, Q.; Tompkins, K.D.; Simonyi, A.; Korthuis, R.J.; Sun, A.Y.; Sun, G.Y. Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. Brain Res. 2006, 1090, 182–189.
  16. Galano, A.; Alvarez-Idaboy, J.R. Glutathione: Mechanism and kinetics of its non-enzymatic defense action against free radicals. RSC Adv. 2011, 1, 1763–1771.
  17. Orian, L.; Cozza, G.; Maiorino, M.; Toppo, S.; Ursini, F. The catalytic mechanism of glutathione peroxidases (Chapter 3). In Glutathione, 1st ed.; Flohé, L., Ed.; CRC Press: Boca Raton, FL, USA, 2018; pp. 35–52.
  18. Couto, N.; Wood, J.; Barber, J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic. Biol. Med. 2016, 95, 27–42.
  19. Hirrlinger, J.; Dringen, R. Multidrug resistance protein 1-mediated export of glutathione and glutathione disulfide from brain astrocytes. Methods Enzymol. 2005, 400, 395–409.
  20. Homolya, L.; Váradi, A.; Sarkadi, B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. BioFactors 2003, 17, 103–114.
  21. Wu, T.; Yin, F.; Kong, H.; Peng, J. Germacrone attenuates cerebral ischemia/reperfusion injury in rats via antioxidative and antiapoptotic mechanisms. J. Cell. Biochem. 2019, 120, 18901–18909.
  22. Li, Z.; Yulei, J.; Yaqing, J.; Jinmin, Z.; Xinyong, L.; Jing, G.; Min, L. Protective effects of tetramethylpyrazine analogue Z-11 on cerebral ischemia reperfusion injury. Eur. J. Pharmacol. 2019, 844, 156–164.
  23. Abdel-Fattah, M.M.; Messiha, B.A.S.; Mansour, A.M. Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: An experimental trial in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 2018, 391, 1003–1020.
  24. Yabuki, Y.; Fukunaga, K. Oral administration of glutathione improves memory deficits following transient brain ischemia by reducing brain oxidative stress. Neuroscience 2013, 250, 394–407.
  25. Anderson, M.F.; Nilsson, M.; Eriksson, P.S.; Sims, N.R. Glutathione monoethyl ester provides neuroprotection in a rat model of stroke. Neurosci. Lett. 2004, 354, 163–165.
  26. Won, S.J.; Kim, J.E.; Cittolin-Santos, G.F.; Swanson, R.A. Assessment at the single-cell level identifies neuronal glutathione depletion as both a cause and effect of ischemia-reperfusion oxidative stress. J. Neurosci. 2015, 35, 7143–7152.
  27. Dringen, R.; Pfeiffer, B.; Hamprecht, B. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione. J. Neurosci. 1999, 19, 562–569.
  28. Frederickson, C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. 1989, 31, 145–238.
  29. Cole, T.B.; Wenzel, H.J.; Kafer, K.E.; Schwartzkroin, P.A.; Palmiter, R.D. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc. Natl. Acad. Sci. USA 1999, 96, 1716–1721.
  30. Danscher, G.; Howell, G.; Pérez-Clausell, J.; Hertel, N. The dithizone, Timm’s sulphide silver and the selenium methods demonstrate a chelatable pool of zinc in CNS. A proton activation (PIXE) analysis of carbon tetrachloride extracts from rat brains and spinal cords intravitally treated with dithizone. Histochemistry 1985, 83, 419–422.
  31. Sensi, S.L.; Paoletti, P.; Bush, A.I.; Sekler, I. Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci. 2009, 10, 780–791.
  32. Frederickson, C.J.; Koh, J.Y.; Bush, A.I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 2005, 6, 449–462.
  33. Frederickson, C.J.; Giblin, L.J.; Krezel, A.; McAdoo, D.J.; Mueller, R.N.; Zeng, Y.; Balaji, R.V.; Masalha, R.; Thompson, R.B.; Fierke, C.A.; et al. Concentrations of extracellular free zinc (pZn)e in the central nervous system during simple anesthetization, ischemia and reperfusion. Exp. Neurol. 2006, 198, 285–293.
  34. Lee, J.Y.; Kim, J.H.; Palmiter, R.D.; Koh, J.Y. Zinc released from metallothionein-III may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp. Neurol. 2003, 184, 337–347.
  35. Koh, J.Y.; Lee, S.J. Metallothionein-3 as a multifunctional player in the control of cellular processes and diseases. Mol. Brain 2020, 13, 116.
  36. Krężel, A.; Maret, W. The functions of metamorphic metallothioneins in zinc and copper metabolism. Int. J. Mol. Sci. 2017, 18, 1237.
  37. Medvedeva, Y.V.; Ji, S.G.; Yin, H.Z.; Weiss, J.H. Differential vulnerability of CA1 versus CA3 pyramidal neurons after ischemia: Possible relationship to sources of Zn2+ accumulation and its entry into and prolonged effects on mitochondria. J. Neurosci. 2017, 37, 726–737.
  38. Maret, W. Oxidative metal release from metallothionein via zinc-thiol/disulfide interchange. Proc. Natl. Acad. Sci. USA 1994, 91, 237–241.
  39. Wang, T.; Zheng, W.; Xu, H.; Zhou, J.M.; Wang, Z.Y. Clioquinol inhibits zinc-triggered caspase activation in the hippocampal CA1 region of a global ischemic gerbil model. PLoS ONE 2010, 5, e11888.
  40. Chen, C.J.; Liao, S.L. Zinc toxicity on neonatal cortical neurons: Involvement of glutathione chelation. J. Neurochem. 2003, 85, 443–453.
  41. Hong, D.K.; Kho, A.R.; Lee, S.H.; Jeong, J.H.; Kang, B.S.; Kang, D.H.; Park, M.K.; Park, K.H.; Lim, M.S.; Choi, B.Y.; et al. Transient receptor potential melastatin 2 (TRPM2) inhibition by antioxidant, n-acetyl-l-cysteine, reduces global cerebral ischemia-induced neuronal death. Int. J. Mol. Sci. 2020, 21, 6026.
  42. Mize, C.E.; Langdon, R.G. Hepatic glutathione reductase. I. Purification and general kinetic properties. J. Biol. Chem. 1962, 237, 1589–1595.
  43. Splittgerber, A.G.; Tappel, A.L. Inhibition of glutathione peroxidase by cadmium and other metal ions. Arch. Biochem. Biophys. 1979, 197, 534–542.